We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
PacificHealth Laboratories Inc (CE) | USOTC:PHLI | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.000001 | 0.00 | 01:00:00 |
Fred Duffner, President and CEO of PacificHealth Laboratories, said, "We have focused our efforts in the first quarter on expanding our audience, improving branding, driving ecommerce sales, and on continued support of new products. To that end during the first quarter:
Mr. Duffner concluded, "We also showed a modest increase in revenues in the first quarter which is traditionally one of our slower quarters prior to the start of the endurance season. We are very pleased with the key branding and consumer messaging changes we were able to implement in just 3 months. I believe these initiatives will support our future growth and success."
About PacificHealth: PacificHealth Laboratories, Inc. (OTCQB: PHLI) (OTCBB: PHLI), a leading nutrition technology company, has been a pioneer in discovering, developing and commercializing patented, protein-based nutritional products that stimulate specific peptides involved in appetite regulation and that activate biochemical pathways involved in muscle performance and growth. PHLI's principal areas of focus include sports performance and weight loss. To learn more, visit www.pacifichealthlabs.com.
Notice: This news release and oral statements made from time to time by Company representatives concerning the same subject matter may contain so-called "forward-looking statements." These statements can be identified by introductory words such as "expects," "plans," "will," "estimates," "forecasts," "projects," or words of similar meaning and by the fact they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing new products and their potential. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known, such as general economic conditions, consumer product acceptance and competitive products, and others of which are not. No forward-looking statements are a guarantee of future results or events, and one should avoid placing undue reliance on such statements.
SELECTED FINANCIAL DATA:
PACIFICHEALTH LABORATORIES, INC. STATEMENTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 2012 AND 2011 (UNAUDITED) Three Months Ended March 31, 2012 2011 ------------- ------------- Revenues: Net product sales $ 1,750,939 $ 1,731,611 Cost of goods sold 1,006,769 960,992 ------------- ------------- Gross profit 744,170 770,619 ------------- ------------- Operating expenses: Sales and marketing 196,413 190,431 General and administrative (Includes related party consulting of $49,145 and $43,000, respectively) 566,243 536,984 Research and development 17,048 14,817 ------------- ------------- 779,704 742,232 ------------- ------------- (Loss) income before other (expense) income and provision for income taxes (35,534) 28,387 ------------- ------------- Other (expense) income: Other income - 2,100 Interest income 113 152 Interest expense (4,428) (3,409) ------------- ------------- (4,315) (1,157) ------------- ------------- (Loss) income before provision for income taxes (39,849) 27,230 Provision for income taxes - - ------------- ------------- Net (loss) income $ (39,849) $ 27,230 ============= ============= Basic (loss) income per share $ 0.00 $ 0.00 ============= ============= Diluted (loss) income per share $ 0.00 $ 0.00 ============= ============= Weighted average common shares - basic 20,871,772 16,665,257 ============= ============= Weighted average common shares - diluted 20,871,772 16,833,590 ============= ============= PACIFICHEALTH LABORATORIES, INC. BALANCE SHEETS (UNAUDITED) ASSETS March 31, December 31, 2012 2011 ------------- ------------- Current assets: Cash and cash equivalents $ 752,900 $ 745,904 Other short-term investments 75,000 75,000 Accounts receivable, net 706,409 369,376 Inventories, net 701,338 571,403 Prepaid expenses 105,161 91,479 ------------- ------------- Total current assets 2,340,808 1,853,162 Property and equipment, net 107,402 26,729 Deposits 10,895 10,895 ------------- ------------- Total assets $ 2,459,105 $ 1,890,786 ============= ============= LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Line of credit $ 37,500 $ 37,500 Notes payable 20,691 19,679 Accounts payable and accrued expenses (Includes related party of $19,586 and $32,000, respectively) 1,130,535 546,712 Deferred revenue 61,554 56,170 ------------- ------------- Total current liabilities 1,250,280 660,061 ------------- ------------- Stockholders' equity: Common stock, $.0025 par value; authorized 50,000,000 shares; issued and outstanding: 20,871,772 shares 52,179 52,179 Additional paid-in capital 21,331,268 21,313,319 Accumulated deficit (20,174,622) (20,134,773) ------------- ------------- 1,208,825 1,230,725 ------------- ------------- Total liabilities and stockholders' equity $ 2,459,105 $ 1,890,786 ============= =============
Contact: Stephen Kuchen 732-739-2900, x603 Email Contact
1 Year PacificHealth Laboratories (CE) Chart |
1 Month PacificHealth Laboratories (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions